X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs DR. REDDYS LAB - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD DR. REDDYS LAB STRIDES SHASUN LTD/
DR. REDDYS LAB
 
P/E (TTM) x 39.8 29.1 137.0% View Chart
P/BV x 1.0 3.1 31.7% View Chart
Dividend Yield % 1.0 0.8 118.3%  

Financials

 STRIDES SHASUN LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
DR. REDDYS LAB
Mar-18
STRIDES SHASUN LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,2752,788 45.7%   
Low Rs9181,902 48.3%   
Sales per share (Unadj.) Rs389.6860.8 45.3%  
Earnings per share (Unadj.) Rs28.057.1 49.0%  
Cash flow per share (Unadj.) Rs48.9122.0 40.1%  
Dividends per share (Unadj.) Rs4.5020.00 22.5%  
Dividend yield (eoy) %0.40.9 48.1%  
Book value per share (Unadj.) Rs303.1757.7 40.0%  
Shares outstanding (eoy) m89.42165.91 53.9%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.82.7 103.3%   
Avg P/E ratio x39.241.1 95.4%  
P/CF ratio (eoy) x22.419.2 116.7%  
Price / Book Value ratio x3.63.1 116.9%  
Dividend payout %16.135.0 45.9%   
Avg Mkt Cap Rs m98,036389,034 25.2%   
No. of employees `0005.823.5 24.7%   
Total wages/salary Rs m5,88132,149 18.3%   
Avg. sales/employee Rs Th6,005.96,070.8 98.9%   
Avg. wages/employee Rs Th1,014.01,366.6 74.2%   
Avg. net profit/employee Rs Th431.2402.5 107.1%   
INCOME DATA
Net Sales Rs m34,834142,810 24.4%  
Other income Rs m1,6861,552 108.6%   
Total revenues Rs m36,520144,362 25.3%   
Gross profit Rs m6,42823,512 27.3%  
Depreciation Rs m1,87210,772 17.4%   
Interest Rs m2,269788 288.0%   
Profit before tax Rs m3,97313,504 29.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m4344 1.0%   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m4704,380 10.7%   
Profit after tax Rs m2,5019,468 26.4%  
Gross profit margin %18.516.5 112.1%  
Effective tax rate %11.832.4 36.5%   
Net profit margin %7.26.6 108.3%  
BALANCE SHEET DATA
Current assets Rs m38,165104,984 36.4%   
Current liabilities Rs m30,40268,938 44.1%   
Net working cap to sales %22.325.2 88.3%  
Current ratio x1.31.5 82.4%  
Inventory Days Days7774 104.0%  
Debtors Days Days104104 100.9%  
Net fixed assets Rs m37,639104,385 36.1%   
Share capital Rs m894830 107.7%   
"Free" reserves Rs m26,210124,886 21.0%   
Net worth Rs m27,105125,716 21.6%   
Long term debt Rs m16,37725,089 65.3%   
Total assets Rs m81,168225,443 36.0%  
Interest coverage x2.818.1 15.2%   
Debt to equity ratio x0.60.2 302.8%  
Sales to assets ratio x0.40.6 67.7%   
Return on assets %5.94.5 129.2%  
Return on equity %9.27.5 122.5%  
Return on capital %12.19.7 124.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46572,623 18.5%   
Fx outflow Rs m4,07618,916 21.5%   
Net fx Rs m9,38953,707 17.5%   
CASH FLOW
From Operations Rs m2,88118,030 16.0%  
From Investments Rs m-7,051-14,883 47.4%  
From Financial Activity Rs m3,382-4,440 -76.2%  
Net Cashflow Rs m-788-1,236 63.7%  

Share Holding

Indian Promoters % 27.7 25.5 108.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 5.4 700.0%  
FIIs % 8.6 35.3 24.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 25.9 15.3 169.3%  
Shareholders   56,241 75,885 74.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Aug 17, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - VENUS REMEDIES COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS